← Russell 3000 cross-section

ENOV Enovis CORP

Trailing twelve months to 2026-07-03 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$2.3bn
Net income TTM
$-1.1bn
Free cash flow
$64m
Composite score
37.7
Sector rank
#1812

Valuation

P / E
EV / EBITDA
8.7
EV / sales
1.2
FCF yield
4.37%
Earnings yield vs 10-yr
-80.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-48.0%
EBITDA margin
13.4%
ROE
-74.6%
ROIC
-38.2%
Revenue growth
4.9%

Insider activity, last 90 days

Net open-market
$0.09m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Of these transactions, three were in the P&R segment and four were in the Recon segment. Foreign Currency Fluctuations During the three and six months ended July 3, 2026, approximately 44% and 45% of our sales, respectively, were derived from operations outside the United States, the majority of which are in Europe, with the remaining portion primarily in the Asia-Pacific region. For the three months ended July 3, 2026 compared to the three months ended July 4, 2025, fluctuations in foreign currencies increased Net sales by 1.0%, increased Gross profit by approximately 0.6%, and increased operating expenses by approximately 0.9%. …Enovis CORP, 10-Q, period ended 2026-07-03, filed 2026-08-06

Read the full passage →